These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8255363)

  • 1. Potent, extra-channel influence of several calcium-channel modulators on striatal binding of [3H]tyramine.
    Vaccari A; Saba P; Gessa G
    Neurochem Res; 1993 Nov; 18(11):1125-30. PubMed ID: 8255363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tyramine binding site in the central nervous system: an overview.
    Vaccari A
    Neurochem Res; 1993 Aug; 18(8):861-8. PubMed ID: 8396735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential interaction of 1-methyl-4-phenylpyridinium ion with the putatively vesicular binding site of [3H]tyramine in dopaminergic and nondopaminergic brain regions.
    Vaccari A; Saba PL; Gessa GL; Del Zompo M
    J Neurochem; 1993 Feb; 60(2):758-60. PubMed ID: 8419550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanthanides stimulate [3H]tyramine binding in the rat striatum.
    Vaccari A; Saba PL; Mocci I; Ruiu S
    Neurosci Lett; 1999 Feb; 261(1-2):49-52. PubMed ID: 10081924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine.
    Vaccari A; Saba PL; Ruiu S; Collu M; Devoto P
    Toxicol Appl Pharmacol; 1996 Jul; 139(1):102-8. PubMed ID: 8685891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of calcium channel blockers on the H(+)-ATPase and bioenergetics of catecholamine storage vesicles.
    Terland O; Grønberg M; Flatmark T
    Eur J Pharmacol; 1991 May; 207(1):37-41. PubMed ID: 1833213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of accumulation of tyramine, metaraminol, and isoproterenol in isolated chromaffin granules and ghosts.
    Johnson RG; Carty SE; Hayflick S; Scarpa A
    Biochem Pharmacol; 1982 Mar; 31(5):815-23. PubMed ID: 7082350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ion channel inhibitors may function as potential modulators of cocaine binding.
    Boja JW; Kopajtic TA
    Neuropharmacology; 1993 Mar; 32(3):229-34. PubMed ID: 7682676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of 1-methyl-4-phenylpyridinium ion and tyramine with a site putatively involved in the striatal vesicular release of dopamine.
    Vaccari A; Del Zompo M; Melis F; Gessa GL; Rossetti ZL
    Br J Pharmacol; 1991 Nov; 104(3):573-4. PubMed ID: 1797320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L; Crooks PA; Dwoskin LP
    J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutically relevant concentrations of neomycin selectively inhibit P-type Ca2+ channels in rat striatum.
    Dobrev D; Ravens U
    Eur J Pharmacol; 2003 Feb; 461(2-3):105-11. PubMed ID: 12586205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins.
    Vaccari A; Saba P
    Eur J Pharmacol; 1995 Mar; 292(3-4):309-14. PubMed ID: 7796871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competitive inhibition of [3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations.
    De Vries DJ; Beart PM
    Eur J Pharmacol; 1984 Oct; 106(1):133-9. PubMed ID: 6241565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High affinity binding of [3H]-tyramine in the central nervous system.
    Vaccari A
    Br J Pharmacol; 1986 Sep; 89(1):15-25. PubMed ID: 3801770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotensin effect on dopamine release and calcium transport in rat striatum: interactions with diphenylalkylamine calcium antagonists.
    Battaini F; Govoni S; Di Giovine S; Trabucchi M
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Mar; 332(3):267-70. PubMed ID: 3713871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes.
    Del Zompo M; Piccardi MP; Ruiu S; Corsini GU; Vaccari A
    Brain Res; 1992 Feb; 571(2):354-7. PubMed ID: 1611504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of [Ca2+]i to dopamine release in striatal synaptosomes: role of Ca2+ channels.
    Carvalho CM; Ferreira IL; Duarte CB; Malva JO; Tretter L; Adam-Vizi V; Carvalho AP
    Brain Res; 1995 Jan; 669(2):234-44. PubMed ID: 7712179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divalent cation competition with [3H]saxitoxin binding to tetrodotoxin-resistant and -sensitive sodium channels. A two-site structural model of ion/toxin interaction.
    Doyle DD; Guo Y; Lustig SL; Satin J; Rogart RB; Fozzard HA
    J Gen Physiol; 1993 Feb; 101(2):153-82. PubMed ID: 8384241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [3H]tyramine binding: a comparison with neuronal [3H]dopamine uptake and [3H]mazindol binding processes.
    Vaccari A; Gessa G
    Neurochem Res; 1989 Oct; 14(10):949-55. PubMed ID: 2532713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of calcium channel inhibition by phenytoin: comparison with classical calcium channel antagonists.
    Messing RO; Carpenter CL; Greenberg DA
    J Pharmacol Exp Ther; 1985 Nov; 235(2):407-11. PubMed ID: 2414431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.